"10.1371_journal.pone.0028092","plos one","2011-12-07T00:00:00Z","Sid E O'Bryant; Guanghua Xiao; Robert Barber; Ryan Huebinger; Kirk Wilhelmsen; Melissa Edwards; Neill Graff-Radford; Rachelle Doody; Ramon Diaz-Arrastia; for the Texas Alzheimer's Research & Care Consortium; for the Alzheimer's Disease Neuroimaging Initiative","Department of Neurology, F. Marie Hall Institute for Rural and Community Health, Garrison Institute on Aging, Texas Tech University Health Sciences Center, Lubbock, Texas, United States of America; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Department of Pharmacology and Neuroscience, Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, Texas, United States of America; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America; Department of Psychology, Texas Tech University, Lubbock, Texas, United States of America; Department of Neurology, Mayo Clinic, Jacksonville, Florida, United States of America; Department of Neurology, Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, Houston, Texas, United States of America; Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences, Rockville, Maryland, United States of America","Conceived and designed the experiments: SEO GX RB RD RDA. Performed the experiments: SEO GX RB KW RD RDA. Analyzed the data: SEO GX RB RH KW ME NGR RD RDA. Contributed reagents/materials/analysis tools: SEO GX RB KW RD RDA. Wrote the paper: SEO GX RB RH KW ME NGR RD RDA.","The authors have the following competing interest: In the TARC, a patent has been submitted on this blood-based screener. There are no other products in development or marketed products to declare. This does not alter the authors' adherence to all PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors. ADNI has received funding from the following commercial sources: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc. This does not alter the authors' adherence to all PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors. ADNI data is freely available to any interested scientists.","2011","12","Sid E O'Bryant","SEOB",11,TRUE,5,6,9,9,TRUE,TRUE,TRUE,2,"10;11",TRUE
